Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-14 2:34 pm Purchase | 13G | Replimune Group Inc. REPL | PRICE T ROWE ASSOCIATES INC | 5,868,638 12.5% | 799,188 (+15.76%) | View |
| 2022-02-09 10:24 am Sale | 13G | Replimune Group Inc. REPL | FMR LLC | 1,054,119 2.247% | -1,572,298 (-59.86%) | View |
| 2021-07-12 2:57 pm Purchase | 13G | Replimune Group Inc. REPL | PRICE T ROWE ASSOCIATES INC | 5,069,450 10.8% | 2,443,759 (+93.07%) | View |
| 2021-02-16 4:11 pm Purchase | 13G | Replimune Group Inc. REPL | Redmile Group LLC | 4,658,043 9.9% | 1,036,408 (+28.62%) | View |
| 2021-02-16 4:05 pm Sale | 13G | Replimune Group Inc. REPL | Coffin Robert | 2,307,300 4.9% | -234,127 (-9.21%) | View |
| 2021-02-16 3:15 pm Sale | 13G | Replimune Group Inc. REPL | Bain Capital Life Sciences Fund L.P. | 0 0% | -2,575,360 (Position Closed) | View |
| 2021-02-16 12:23 pm Purchase | 13G | Replimune Group Inc. REPL | PRICE T ROWE ASSOCIATES INC | 2,625,691 5.7% | 2,625,691 (New Position) | View |
| 2021-02-16 06:36 am Unchanged | 13G | Replimune Group Inc. REPL | Forbion Capital Fund III Cooperatief U.A. | 5,115,121 11.13% | 0 (Unchanged) | View |
| 2021-02-11 5:12 pm Sale | 13G | Replimune Group Inc. REPL | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -2,309,109 (Position Closed) | View |
| 2021-02-08 10:31 am Purchase | 13G | Replimune Group Inc. REPL | FMR LLC | 2,626,417 5.714% | 2,626,417 (New Position) | View |
| 2020-09-17 4:50 pm Sale | 13D | Replimune Group Inc. REPL | Atlas Venture Fund X L.P. | 2,524,866 6.3% | -436,607 (-14.74%) | View |
| 2020-07-07 5:11 pm Sale | 13D | Replimune Group Inc. REPL | Atlas Venture Fund X L.P. | 2,961,473 7.5% | -436,607 (-12.85%) | View |
| 2020-06-19 5:03 pm Sale | 13D | Replimune Group Inc. REPL | Atlas Venture Fund X L.P. | 3,398,080 8.6% | -436,507 (-11.38%) | View |
| 2020-02-14 4:25 pm Purchase | 13G | Replimune Group Inc. REPL | Redmile Group LLC | 3,621,635 9.9% | 1,432,679 (+65.45%) | View |
| 2020-02-14 2:39 pm Purchase | 13G | Replimune Group Inc. REPL | BIOTECHNOLOGY VALUE FUND L P | 2,309,109 6.5% | 702,292 (+43.71%) | View |
| 2020-02-14 1:14 pm Purchase | 13G | Replimune Group Inc. REPL | Omega Fund IV L.P. | 5,329,783 16.5% | 226,328 (+4.43%) | View |
| 2020-02-14 10:00 am Purchase | 13G | Replimune Group Inc. REPL | Coffin Robert | 2,541,427 6.9% | 3,325 (+0.13%) | View |
| 2020-02-13 9:16 pm Sale | 13G | Replimune Group Inc. REPL | Foresite Capital Fund III L.P. | 313,922 0.8% | -1,695,390 (-84.38%) | View |
| 2020-02-11 5:05 pm Purchase | 13G | Replimune Group Inc. REPL | Forbion Capital Fund III Cooperatief U.A. | 5,115,121 14.45% | 145,000 (+2.92%) | View |
| 2019-11-25 5:17 pm Sale | 13D | Replimune Group Inc. REPL | Atlas Venture Fund X L.P. | 3,834,587 10.8% | -618,799 (-13.90%) | View |